Outline

- N-linked Glycopeptides are better resolved using HILIC compared to reversed phase HPLC
- Analysis of synthetic peptides and protein digests with trypsin fragments is readily accomplished using Hydrophilic Interaction Liquid Chromatography (HILIC), exhibiting resolution and efficiencies that are improved over reversed phase HPLC
- A mixture of synthetic peptides representing a site of IgG that is known to be prone to asparagine deamidation, and subsequently to form a mixture of aspartate and iso-aspartate peptides, has been examined by HILIC LC/MS, as have asparagine and aspartate containing proteolytic fragments derived from a humanized monoclonal IgG1 biotherapeutic.
- A variety of deamidation and iso-aspartate sensitive sites are detected in peptide fragments from this IgG, and several show significant changes in relative amounts when the protein is stressed for 7 days by incubation at pH 9, at a temperature of 37°C.

Introduction

Post-translational modifications (PTMs) include biochemical changes to the protein, such as changes to the amino acid side chain functional groups, the Ntermini, and peptide hydrolysis. Many PTMs are polar by nature and lend themselves to improved analysis via hydrophilic interaction liquid chromatography (HILIC) because these modified peptide and protein forms are often better retained and resolved compared to reversed-phase (RP). PTMs must be characterized and controlled for effective and safe biotherapeutic development, such as monoclonal antibody treatments. As additional mAb biotherapeutics and biosimilars enter development, the focus on PTM characterization is expanding and can lead to better understanding their impact on biotherapeutics. Here we specifically investigate glycosylation and deamidation modifications.

Materials and Methods

mAb IgGs and standard proteins were commercially obtained and dissolved at 1 2 mg/mL in either 0.1% formic acid (FA) or trifluoroacetic acid (TFA). Columns of HALO 160 Å ES-C18, HALO 90 Å Penta-HILIC, and HALO 90 Å Glycan all 2.7 μm diameter silica particles (Advanced Materials Technology, Inc., Wilmington, DE) were compared for MS spectral quality, column retention, peak widths and tailing factors. 2.1 mm or 0.2 mm ID columns were eluted using increasing acetonitrile or increasing water, modified with ammonium formate/formic acid. ESI/MS detection used the Thermo Velos Pro LTQ Orbitrap hybrid instrument, with XCalibur data capture, and Chromeleon (XIC) and PD4.0 (deconvolution) for analysis.

Importance of Glycosylation

- Impacts the safety/immunogenicity
- Influences the efficacy and clearance
- Impacts the stability and solubility
- As a critical quality attribute, must be characterized





(Neu5Ac)







Table 1. Paired comparison of RP and HILIC for Glycopeptide/Peptide LC/MS. The 26 peptides shown were analyzed by LC/MS using 2.1 x 100 mm columns, with a flow rate of 0.4 mL/min at 60°C. Gradient conditions: A – 0.1% formic acid/10 mM ammonium formate; B – 90% Acetonitrile in A. 500 pmol was injected, with detection at 210 nm, MS operated +4.5 kV, with 0.45 s scan from 500 to 2000 m/z. RP Gradient - 4% to 34% AcN/30 min (1%/min); HILIC Gradient - 90% to 60% AcN/30 min (-1%/min). The sequences were selected based on known O-HexNAc modified sites in a variety of proteins. Peak widths; means were 0.092 min. for RP and 0.090 min. for HILIC. Average and variance in Rt for the modes were similar.

		Mass		Δ Rt RP			Δ Rt HILIC	5	
Peptide Description	Sequence	(neutral)	Rt RP (min)	(GP-P)	RS RP	Rt HILIC (min)	(GP-P)	RS HILIC	
APP695-14GPep		1574.8	5.87			21.55			
APP695-14Pep	VPTTAASTPDAVDK	1371.7	6.11	-0.24	1.90	19.49	2.07	9.41	
MUC5AC	GTTPSPVPTTSTTSAP	1501.6	9.28			16.41			•
MUC5AC-3	GTT(OGalNAc)PSPVPTTSTTSAP	1704.6	8.45	-0.83	6.88	18.68	2.27	13.40	A
MUC5AC-13	GTTPSPVPTTSTT(OGalNAc)SAP	1704.6	8.53	-0.75	5.82	18.51	2.10	10.72	
MUC5AC3/13	GTT(OGalNAc)PSPVPTTSTT(OGalNAc)S	AP 1908.1	7.76	-1.52/2	11.84	20.48	4.07/2	23.35	
GP-41	Ac-CSTFRPRT(OGIcNAc)SSNAST	1758.8	7.09			18.59			
2-42	Ac-CSTFRPRTSSNAST	1555.7	7.03	0.06	0.44	17.03	1.56	11.58	
GP-78	Ac-CQHPPVT(OGlcNAc)NGDTVK	1639.8	6.47			20.32			
P-84	Ac-CQHPPVTNGDTVK	1436.7	6.56	-0.10	0.66	18.72	1.61	11.23	
GP-79	Ac-CKIADFGLS(OGIcNAc)KIVEHQ	1932.0	19.36			19.15			
P-85	Ac-CKIADFGLSKIVEHQ	1728.9	20.80	-1.44	8.16	17.21	1.94	14.76	
GP-17s	CTLHTKAS(OGIcNAc)GMALLHQ	1854.9	13.62			17.29			
2-20s	CTLHTKASGMALLHQ	1651.8	14.23	-0.61	3.06	15.15	2.14	15.38	
GP-15	Ac-CFELLPT(O-GIcNAc)PPLSP	1557.8	25.16			5.64			
P-18	Ac-CFELLPTPPLSP	1354.7	27.16	-2.00	8.88	2.71	2.93	20.11	Ν
GP-46	Ac-CRSSHYGGS(OGIcNAc)LPNVNQI	1975.9	12.48			17.32			I
P-47	Ac-CRSSHYGGSLPNVNQI	1772.8	12.96	-0.48	3.83	15.43	1.89	13.91	
GP-51	Ac-CSALNRTS(OGIcNAc)SDSALHT	1806.8	9.08			17.23			
P-52	Ac-CSALNRTSSDSALHT	1603.7	9.55	-0.47	3.85	15.55	1.69	12.42	
GP-16	Ac-CKIPGVS(OGlcNAc)TPQTL	1487.7	16.41			13.27			
P-19	Ac-CKIPGVSTPQTL	1284.6	16.98	-0.58	3.74	10.59	2.68	21.63	
GP-2-p53	Ac-CQLWVDS(OGlcNAc)TPPPG	1543.7	16.43			12.72			
P-3-p53	Ac-CQLWVDSTPPPG	1340.6	17.66	-1.23	7.23	10.41	2.31	10.28	
GP-17r	Ac-CLHTKAS(OGIcNAc)GMALL	1488.7	16.21			10.59			
2-20r	Ac-CLHTKASGMALL	1285.6	16.98	-0.77	2.79	7.45	3.14	24.73	
	Ave	age	13.01	-0.73	4.93	15.29	2.17	15.21	
	Star	dard Deviation	5.95	0.54	3.32	4.74	0.47	5.13	
			45.7		67.2	21.0	21.0	22.7	
	70 K.	U	45.7	/4.5	07.5	51.0	21.0	55./	





Source: https://www.glytech-inc.com/glycan/what-are-glycans/

LC/MS HILIC Analysis for Glycosylation and Deamidation of Peptides and mAbs

Stephanie A. Schuster, Andrew F. Harron, Benjamin P. Libert, and Barry E. Boyes Advanced Materials Technology, Inc., Wilmington, DE

HILIC Strongly Retains and Resolves N-linked Glycopeptides



RP: 2-58.2%B in B in 45 min (1% ACN/min) B-80% ACN/0.1% FA/10 mM AmmForm **No resolution of high mannose variant glycopeptides**

RP and HILIC of Peptide/Glycopeptide Pairs



Huang, Y., Nie, Y., Boyes, B., and Orlando, R. (2016) J. Biomol. Technol., 27, 98-104.



HILIC for Deamidation and Isomerization Detection in Peptides & mAbs



Trastuzumab Light Chain										
	25	ASQDV <u>N</u> TAVAWYQQKPGK	42	N ³⁰ T						
Trastuzumab Heavy Chain										
	76	NTAYLQM <u>N</u> SLR	86	N ⁸³ S						
	99	WGG <mark>DG</mark> FYAMDYWGQGTLVTVSSASTK	124	D ¹⁰² G						
	279	FNWYV <mark>DG</mark> VEVHNAK	292	D ²⁸⁴ G						
	306	VVSVLTVLHQDWL <u>N</u> GK	321	N ³¹⁹ G						
	375	GFYPSDIAVEWES <u>N</u> GQPE <u>N</u> NYK	396	N ³⁸⁸ GNN ³⁹³ N ³⁹⁴ Y						
	421	WQQG <u>N</u> VFSCSVMHEALH <u>N</u> HYTQK	443	N ⁴²⁵ VN ⁴³⁸ H						

ASQDVNTAVAWYQQKPGK

advancedmaterialstechnology

ASMS 2021: TP 287

Deamidation and Isomerization in IgG Tryptic Digests

Trypsin digestion of the mAb IgG for native protein (as obtained for pharmaceutical purposes), and on samples that were "stressed" by incubation in Tris-HCl pH 9.0 for 7 days at 4 mg/mL. Reduced and alkylated proteins were digested at 1:30 protein to enzyme for 4hrs in 50 mM Tris-HCl (pH 7.8)/1.5M Guanidine-HCl, followed by formic acid acidification and direct injection on to capillary LC/MS using the Orbitrap/IT. Extracted ions at the monoisotopic masses of the target sequences were integrated; the reported sequences were confirmed in CID MS/MS fragmentation, with the exception of sN sequences of low abundance (sN³⁸⁸G confirmed, but not sN sequence eluting at 26.7 min.). Not all deamidation products are determinate as iD or D residues, due to the similarity of CID fragmentation. ETD studies are ongoing. Relative values of modifications compared to native total Asn or Asp sequences reproducibly obtained, and retention positions for all confidently identified modifications are noted, with comparison to retention position predicted by the current model.

GFYPSDIAVEWES<u>N</u>GQPE<u>N</u>NYK in Trastuzumab Digest

Native





WGGDGFYAMDYWGQGTLVTVSSASTK in Trastuzumab Digest

Native



Stressed XIC 1392.580-1392.680 m/ XIC 1383.580-1383.680 m

- 9 sites of potential modification were analyzed 3 Asn sites with significant deamidation, and subsequent isomerization.
 - 2 sites showed presence of D/iD pairs, neither were strongly affected by "stress"
- All susceptible sites exhibited the cyclic intermediate sN, whether formed from D or N in the native sequence.

Conclusions and Future Directions

- HILIC separations show increased resolution of polar PTMs of mAbs compared to reversedphase separations
- HALO 90 Å Glycan is well suited for separations of glycovariants and analysis of site occupancy
- Glycosylation analysis using HALO 90 Å Glycan results in separation of isomeric glycans
- A high efficiency and reliable HILIC separation approach was applied to resolution of modified Asn and Asp peptides and tryptic fragments of intact proteins. Resolution of polar modifications was excellent.
- The combination of high resolution separation with high resolution MS permits effective analysis of deamination and isomerization products, with resolution of Asn, Asp, isoAsp and succinimidyl intermediates.